OncoZenge (ONCOZ) Rights Issue Subscribed ~92%

OncoZenge said its rights issue concluded at approximately 92% subscription.Material DetailsContext by AI AnalystThis is a financing update, reinforcing the company's ability to raise capital but with a small shortfall. A larger catalyst would require details on proceeds, allocation of any unsubscr…